Cartesian Therapeutics (RNAC) Competitors $10.41 -0.36 (-3.34%) Closing price 04:00 PM EasternExtended Trading$10.00 -0.41 (-3.94%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAC vs. MLYS, PAHC, RCUS, WVE, SNDX, COLL, ELVN, SYRE, NRIX, and NAGEShould you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Mineralys Therapeutics (MLYS), Phibro Animal Health (PAHC), Arcus Biosciences (RCUS), Wave Life Sciences (WVE), Syndax Pharmaceuticals (SNDX), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Spyre Therapeutics (SYRE), Nurix Therapeutics (NRIX), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Cartesian Therapeutics vs. Its Competitors Mineralys Therapeutics Phibro Animal Health Arcus Biosciences Wave Life Sciences Syndax Pharmaceuticals Collegium Pharmaceutical Enliven Therapeutics Spyre Therapeutics Nurix Therapeutics Niagen Bioscience Mineralys Therapeutics (NASDAQ:MLYS) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Do insiders & institutionals have more ownership in MLYS or RNAC? 84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are held by institutional investors. 25.6% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer MLYS or RNAC? In the previous week, Cartesian Therapeutics had 4 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 6 mentions for Cartesian Therapeutics and 2 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.82 beat Cartesian Therapeutics' score of 1.47 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cartesian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate MLYS or RNAC? Mineralys Therapeutics currently has a consensus target price of $32.25, indicating a potential upside of 107.40%. Cartesian Therapeutics has a consensus target price of $43.00, indicating a potential upside of 313.06%. Given Cartesian Therapeutics' higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is MLYS or RNAC more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -67.97% -62.40% Cartesian Therapeutics -510.72%N/A -6.03% Which has more risk & volatility, MLYS or RNAC? Mineralys Therapeutics has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Which has better earnings & valuation, MLYS or RNAC? Mineralys Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.73-4.17Cartesian Therapeutics$34.17M7.91-$219.71M-$52.83-0.20 Does the MarketBeat Community favor MLYS or RNAC? Cartesian Therapeutics received 19 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. Likewise, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 86.96% of users gave Mineralys Therapeutics an outperform vote. CompanyUnderperformOutperformMineralys TherapeuticsOutperform Votes2086.96% Underperform Votes313.04%Cartesian TherapeuticsOutperform Votes3995.12% Underperform Votes24.88% SummaryCartesian Therapeutics beats Mineralys Therapeutics on 12 of the 17 factors compared between the two stocks. Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAC vs. The Competition Export to ExcelMetricCartesian TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$270.18M$6.85B$5.57B$8.61BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-0.208.7827.1720.06Price / Sales7.91255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book-0.136.557.064.70Net Income-$219.71M$143.93M$3.23B$247.88M7 Day Performance9.12%3.74%2.68%2.20%1 Month Performance4.41%13.94%12.02%9.44%1 Year Performance-66.12%4.62%31.24%14.72% Cartesian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNACCartesian Therapeutics1.9204 of 5 stars$10.41-3.3%$43.00+313.1%-66.7%$270.18M$34.17M-0.2064News CoveragePositive NewsAnalyst RevisionGap UpMLYSMineralys Therapeutics3.319 of 5 stars$15.70+0.8%$38.00+142.0%+18.7%$1.02BN/A-4.3128Positive NewsAnalyst ForecastPAHCPhibro Animal Health3.8636 of 5 stars$24.58+0.7%$20.00-18.6%+43.8%$996.33M$1.19B51.211,860Positive NewsRCUSArcus Biosciences2.4877 of 5 stars$9.21+3.1%$24.13+162.1%-37.7%$974.67M$141M-2.92500News CoverageOptions VolumeAnalyst RevisionWVEWave Life Sciences4.464 of 5 stars$6.25+4.0%$21.17+238.7%+22.5%$963.34M$104.94M-5.63240Positive NewsAnalyst ForecastAnalyst RevisionSNDXSyndax Pharmaceuticals2.9903 of 5 stars$10.98+4.2%$35.91+227.0%-43.0%$944.80M$43.72M-3.02110Positive NewsCOLLCollegium Pharmaceutical3.9441 of 5 stars$29.31+0.6%$43.80+49.4%-8.8%$941.79M$664.28M12.63210Positive NewsInsider TradeELVNEnliven Therapeutics2.4496 of 5 stars$19.14+7.7%$37.25+94.6%-3.9%$939.18MN/A-10.0750Insider TradeSYRESpyre Therapeutics2.1525 of 5 stars$15.40+0.8%$53.40+246.8%-49.1%$928.25M$890K-2.0673NRIXNurix Therapeutics2.0961 of 5 stars$12.14+14.2%$30.44+150.8%-16.5%$925.51M$56.42M-4.20300Positive NewsGap UpHigh Trading VolumeNAGENiagen Bioscience1.4559 of 5 stars$11.73+8.4%$13.00+10.8%N/A$923.97M$107.93M69.00120News CoverageAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies MLYS Competitors PAHC Competitors RCUS Competitors WVE Competitors SNDX Competitors COLL Competitors ELVN Competitors SYRE Competitors NRIX Competitors NAGE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAC) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
